GGrantIndex
Sort

48,018 grants matching immunotherapy

Hexokinase 2 and cancer therapy

$574,013
Nissim Hay · University Of Illinois At Chicago · R01 · FY2025 · CA

Single Cell Methods for Bioeffector Discovery and Analysis

$573,883
Brian O Bachmann · Vanderbilt University · R01 · FY2020 · CA

Immunotherapeutic Modulation of Peanut Allergy

$573,881
Scott H Sicherer · Icahn School Of Medicine At Mount Sinai · U19 · FY2006 · AI

IDENTIFYING BIOMARKERS OF RESPONSE AND RESISTANCE TO IMMUNOTHERAPY IN BLADDER CANCER

$573,850
The Cleveland Clinic Foundation · · FY2020 · Defense Health Agency

The Role of the Tumor Suppressor ARID1A in R loop Homeostasis and Tumor Immunity

$573,836
Diana Clare Hargreaves · Salk Institute For Biological Studies · R01 · FY2025 · CA

Fecal Microbiota Transplant and PD-1 blockade in Melanoma

$573,831
Hassane M Zarour · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · CA

A NON-HUMAN PRIMATE MODEL OF TUBERCULOSIS AND AIDS

$573,820
University Of Pittsburgh At Pittsburgh · R01 · FY2001 · AI

A HIGHLY SUPERIOR AND SELECTIVE CANCER IMMUNOTHERAPY-BASED APPROACH FOR TRIPLE-NEGATIVE BREAST CANCERS

$573,784
Rector & Visitors Of The University Of Virginia · · FY2018 · Defense Health Agency

High-Specificity Imaging Agents for Aggressive Prostate Cancer

$573,775
Martin G Pomper · Johns Hopkins University · R01 · FY2015 · CA

Pathways, a Hope-Based Intervention to Support Personal Goal Pursuit, Mental Health, and Quality of Life during Advanced Lung Cancer Treatment

$573,726
Laurie McLouth · University Of Kentucky · R01 · FY2025 · CA

Vaccine and radiation for the therapy of human cancers

$573,692
James Hodge · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

Vaccine and Drug Combination Therapy for Human Cancers

$573,692
James Hodge · Division Of Basic Sciences - Nci · ZIA · FY2016 · CA

Novel therapeutic approaches for enhancing anti-tumor immunity in SCLC

$573,659
John V. Heymach · University Of Tx Md Anderson Can Ctr · U01 · FY2019 · CA

Elucidating genetics of response to immune checkpoint blockade in lung cancer

$573,644
Naiyer A Rizvi · Columbia University Health Sciences · R01 · FY2017 · CA

Induced tolerogenic dendritic cell therapy of allergic diseases

$573,633
Ulrich H Von Andrian · Massachusetts General Hospital · U19 · FY2013 · AI

Metabolism of cancer chemotherapeutics by the human gut microbiome

$573,622
Peter James Turnbaugh · University Of California, San Francisco · R01 · FY2024 · CA

Activating Native Tumor Immunity with IL-33 Armored CARs

$573,520
Yina Hsing Huang · Dartmouth College · R01 · FY2023 · CA

Whitlockite nanoparticle-based immunotherapy for bone metastasis

$573,510
Shiladitya Sengupta · Brigham And Women'S Hospital · R01 · FY2019 · CA

Circulating biomarkers of clinical response to combination targeted therapies in neuroblastoma

$573,379
Kieuhoa Tran Vo · University Of California, San Francisco · R01 · FY2024 · CA

IMMUNOBIOLOGY OF NORMAL AND NEOPLASTIC LYMPHOCYTES

$573,371
Warren S Pear · University Of Pennsylvania · T32 · FY2016 · CA

Leveraging canine spontaneous cancer to optimize the power of blood biopsy

$573,297
Elinor Karlsson · Univ Of Massachusetts Med Sch Worcester · R01 · FY2023 · CA

Characterization of high-grade serous ovarian cancer subtypes via single-cell profiling

$573,258
Casey S Greene · University Of Colorado Denver · R01 · FY2022 · CA

Neutrophil derived proteinases abolish the IFNG signature in NSCLC

$573,105
A. McGarry Houghton · Fred Hutchinson Cancer Center · R01 · FY2023 · CA

Credentialing Models of Invasive Lobular Breast Cancer for Translational Research

$573,041
Steffi Oesterreich · University Of Pittsburgh At Pittsburgh · R01 · FY2021 · CA

Development of selective HDAC6 inhibitors to improve cancer immunotherapy

$573,024
Alejandro V Villagra · Georgetown University · R01 · FY2025 · CA